GlassScriptPhysician profile
John R Pittman
NPI 1588646988
$38,544.17
in general payments reported to CMS, 2019-2025
63 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $2,680 · 2021: $10K · 2022: $14K · 2024: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $137.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18,599.90 | 2021-2022 | |
| Lilly USA, LLC | $4,321.25 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,642.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $2,154.95 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,047.17 | 2019-2021 | |
| Novo Nordisk INC | $889.67 | 2019-2024 | Wegovy |
| Otsuka America Pharmaceutical, INC. | $830.15 | 2019-2021 | |
| Amgen INC. | $768.28 | 2019-2021 | |
| Esperion Therapeutics, INC. | $482.45 | 2020-2021 | |
| Daiichi Sankyo INC. | $467.34 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $389.44 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.75 | 2019-2021 | |
| Amarin Pharma, INC. | $384.62 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $312.71 | 2019-2021 | |
| Relievant Medsystems, INC. | $261.32 | 2021-2022 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pittman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.